¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Wiskott-Aldrich Syndrome Protein"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • radicular syndrome
    ½Å°æ»Ñ¸®ÁõÈıº, ½Å°æ±ÙÁõÈıº
  • retraction syndrome
    ¾È±¸ÈÄÅðÁõÈıº
  • scalded skin syndrome
    È­»óÇǺÎÁõÈıº
  • staphylococcal scalded skin syndrome
    Æ÷µµ¾Ë±Õ¼º¿­»óÇǺÎÁõÈıº, Æ÷µµ±¸±Õ¼º¿­»óÇǺÎÁõÈıº
  • stasis syndrome
    âÀÚÁ¤Ã¼ÁõÈıº, ÀåÁ¤Ã¼ÁõÈıº
  • Steele-Richardson-Olszewski syndrome
    ½ºÆ¿-¸®Ã³µå½¼-¿Ã½ºÁ¦ºê½ºÅ°ÁõÈıº
  • Scheie syndrome
    »þÀÌ¿¡ÁõÈıº
  • Stevens-Johnson syndrome
    ½ºÆ¼ºì½º-Á¸½¼ÁõÈıº
  • stiff-man syndrome
    °­Á÷ÁõÈıº
  • streptococcal toxic shock syndrome
    »ç½½¾Ë±Õµ¶¼º¼îÅ©ÁõÈıº, ¿¬¼â±¸±Õµ¶¼º¼îÅ©ÁõÈıº
  • sudden infant death syndrome
    ¿µ¾Æµ¹¿¬»çÁõÈıº
  • superior mesenteric artery syndrome
    À§Ã¢ÀÚ°£¸·µ¿¸ÆÁõÈıº, À§Àå°£¸·µ¿¸ÆÁõÈıº
  • superior orbital fissure syndrome
    À§´«È®Æ´»õÁõÈıº, »ó¾È¿Í¿­ÁõÈıº
  • superior vena cava syndrome
    À§´ëÁ¤¸ÆÁõÈıº, »ó´ëÁ¤¸ÆÁõÈıº
  • supine hypotensive syndrome
    ´©¿îÀÚ¼¼ÀúÇ÷¾ÐÁõÈıº, ¾Ó¿ÍÀ§ÀúÇ÷¾ÐÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • Riley-Smith syndrome
    ¸±¸® ½º¹Ì½º ÁõÈıº
  • Robinsons syndrome
    ·Îºó½¼ ÁõÈıº
  • Rombergs disease = Romberg syndrome
    ·Òº£¸£Å©º´
  • Rosenthal-Kloepfer syndrome
    ·ÎÁ¨Å» Ŭ·Î¿¡ÆÛ ÁõÈıº
  • Roth-Bielschowsky syndrome
    ·ÎÆ®-ºô¼î½ºÅ°ÁõÈıº
  • Rubinstein-Taybi syndrome
    ·çºó½ºÅ¸ÀÎ Å×À̺ñ ÁõÈıº
  • Ruds syndrome
    ·¯µå ÁõÈıº
  • Russell-Silver syndrome
    ·¯¼¿ ½Ç¹ö ÁõÈıº
  • Seckels syndrome = bird-headed dwarf
    »õ¸Ó¸® ¿Ö¼ÒÁõ
  • Sertoli cell only syndrome
    ½áÅ丮 ¼¼Æ÷ ÁõÈıº
  • Sezarys syndrome
    ¼¼ÀÚ¸®ÁõÈıº
  • Silver syndrome =Russell Silver s.
    ½Ç¹öÁõÈıº(¡­ñøý¦ÏØ).
  • Sj grens syndrome
    ¼î±×·»ÁõÈıº
  • Sjo gren s syndrome
    ¼î±×·»ÁõÈıº.
  • Sjogrens syndrome
    ¼î±×·»ÁõÈıº
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • blue rubber-bleb nevus syndrome
    û»ö°í¹«¼öÆ÷¸ð¹ÝÁõÈıº
  • blue rubber-bleb nevus syndrome
    û»ö°í¹«¼öÆ÷¸ð¹ÝÁõÈıº(ôìßä¡­â©øÜÙ½Úèñøý¦ÏØ)
  • borderline syndrome
    °æ°è¼º ÁõÈıº
  • bradycardia tachycardia syndrome
    ¼­ºó¸Æ ÁõÈıº(ßïÞµØæ ñøý¥ÏØ).
  • bradycardia tachycardia syndrome
    ¼øÈ¯¼­¸Æºó¸ÆÁõÈıº.
  • bradytachycardia syndrome
    ¼­ºó¸ÆÁõÈıº(ßïÞºØæñøý¦ÏØ).
  • brain death syndrome
    ³ú»çÁõÈıº(ÒàÞÝñøý¦ÏØ).
  • brain stem syndrome
    ³ú°£ÁõÈıº(¡­ñøý¦ÏØ).
  • brain syndrome
    ³úÁõÈıº
  • brain syndrome, acute, chronic
    ±Þ¼º, ¸¸¼º ³úÁõÈıº.
  • breast/ovarian familial cancer syndrome
    À¯¹æ/³­¼Ò °¡Á·¼º ¾ÏÁõÈıº
  • brittle hair syndrome
    Ãë¾à¸ð¹ßÁõÈıº
  • broad thumb-hallux syndrome
    ±¤¾öÁö¼Õ,¹ß°¡¶ôÁõÈıº
  • bronze baby syndrome
    ûµ¿»ö¾Æ±âÁõÈıº
  • bruising syndrome
    Ÿ¹Ú»óÁõÈıº.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
CAS calcarine sulcus; calcific aortic stenosis; Cancer Attitude Survey; carbohydrate-active steroid; car...
CBS cervicobrachial syndrome; chronic brain syndrome; clinical behavioral science; conjugated bile salts...
CHS central hypoventilation syndrome; Chediak-Higashi syndrome; cholinesterase; chondroitin sulfate; com...
CPS carbamoylphosphate synthetase; cardioplegic perfusion solution; centipoise; cervical pain syndrome; ...
CRS Carroll rating scale for depression; catheter-related sepsis; caudal regression syndrome; cervical s...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
FS Fanconi syndrome
FES Fat Embolism Syndrome
FLHS Fatty Liver Haemorrhagic Syndrome
FLKS Fatty Liver and Kidney Syndrome
FS Felty syndrome
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lobotomy syndrome
    ³ú¿± Àý´Ü¼ú ÁõÈıº
  • lock pin ¼±´ÜÀº taperÇÏ°í µÎºÎ´Â ±¸»óÀ¸·Î µÇ¾î ÀÖ´Â Ä¡³»°ñ³» ¸Å½ÄüÀÇ ÀÏÁ¾.

    locked-in syndrome

    Æó¼â ÁõÈıº
  • long tract syndrome
    Àå°æ·Î ÁõÈıº
  • low output syndrome
    Àú ¹ÚÃâ·® ÁõÈıº
  • low salt syndrome
    Àú¿° ÁõÈıº
  • lower nephron syndrome
    ÇϺΠ³×ÇÁ·Ð ÁõÈıº
  • lupus erythematosus like syndrome
    È«¹Ý¼º ·çǪ½º¾ç ÁõÈıº
  • lupus-like syndrome
    ³¶Ã¢ ¾ç»óÀÇ ÁõÈıº
  • luxury perfusion syndrome
    ȣȭ °ü·ù ÁõÈıº
  • Lyell syndrome
    Lyell ÁõÈıº
  • malabsorption syndrome
    Èí¼öÀå¾Ö ÁõÈıº
    Á¤°ü¿¡¼­ÀÇ ¿µ¾ç¹° Èí¼öÀÇ Àå¾Ö¸¦ °¡Á®¿À´Â ÁúȯÀ» ÃѰýÇÏ´Â ¸íĪ. ¼³»ç, üÁß °¨¼Ò, ¿µ¾ç½ÇÁ¶¸¦ °¡Á®¿À´Â ¿øÀÎÀÌ µÇ´Â ÁúȯÀº Àå°ü ¼ö¼ú µÚ, Àå Áúȯ, ÃéÀå Áúȯ, °£´ãµµ Áúȯ, ¸²ÇÁÁ¾, ½ÉºÎÀü, ½É³¶¿°, ¾Æ´Ò·ÎÀ̵å½Ã½º, ¥â-Áö¹æ ´Ü¹é °á¼ÕÁõ, ½ºÇª·ç¿ì
  • maladaptation syndrome
    ÀûÀÀ Àå¾Ö ÁõÈıº
  • male Turners syndrome
    ³²¼º ÅÍ³Ê ÁõÈıº
  • malignant hyperthermia syndrome
    ¾Ç¼º °í¿­ ÁõÈıº
  • Mallory-Weiss syndrome
    ¸»·Î¸®-¹ÙÀ̽º ÁõÈıº, ¸È·Î¸®¿ÍÀ̽º ÁõÈıº
    1. ±¸Åä¿¡ ÀÇÇØ ½ÄµµÀ§ °áÇÕºÎÀÇ Á¡¸· ¿­»óÀ» ¸»Çϴµ¥, ¹ß»ý ±âÀüÀ¸·Î´Â ½ÉÇÑ ±¸Åä ½Ã °©ÀÛ½º·± º¹¾ÐÀÇ »ó½ÂÀÌ ¿øÀÎÀÌ µÇ¸ç ȯÀÚ´Â ÁßÁõ ¾ËÄÚ¿Ã Áßµ¶°ú °ü·ÃµÈ ¸¸¼º ±¸ÅäÁõÀÌ ÀÖ´Ù. º´¸® ¼Ò°ßÀ¸·Î´Â À§Àå »óºÎ°¡ º¸Åë ħ¹üµÇ¸ç À§ ºÐ¹®ÀÇ ´ë¸¸ÀÌ °¡Àå ÈçÈ÷ ħ¹üµÈ´Ù. ÅëÁõÀº ¾øÀÌ À§Àå ÃâÇ÷ÀÌ »ý±ä´Ù. ÃâÇ÷ Áõ»óÀº Ç÷º¯º¸´Ù´Â ÅäÇ÷ÀÇ ÇüÅ·Πº¸Åë ³ªÅ¸³­´Ù. Áø´ÜÀº ³»½Ã°æÀ¸·Î Á¡¸· ¿­»óÀ» Áõ¸íÇÏ¿© È®ÁøÇϸç Ä¡·á´Â À§ Àå°ü ÃâÇ÷¿¡ ´ëÇÑ ´ëÁõÀû ¿ä¹ýÀ» ¸ÕÀú ½ÃÀÛÇÏ¿© ¸¸ÀÏ ÃâÇ÷ÀÌ Áö¼ÓµÇ¸é Áï½Ã ¼ö¼úÀ» ½ÃÇàÇÑ´Ù. ¼ö¼ú ÈÄ ¿¹ÈÄ´Â ÁÁ´Ù. 2. ½ÉÇÑ ±¸Åä¿Í ±¸¿ªÀÌ ¸î ½Ã°£ ¶Ç´Â ¸çÄ¥°£ Áö¼ÓµÈ ÈÄ¿¡ ÅäÇ÷, ÇÏÇ÷À» ÀÏÀ¸Å°´Â Áúȯ. 1929³â ¹Ì±¹ º´¸®ÇÐÀÚ G.K. ¸È·¯¸®¿Í ³»°úÀÇ»ç S. ¿ÍÀ̽º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
protein-tyrosine-phosphatase <enzyme> An enzyme group that specifically dephosphorylates phosphotyrosyl residues in selected proteins. Together with protein-tyrosine kinase, it regulates tyrosine phosphorylation and dephosphorylation in cellular signal transduction and may play a role in cell growth control and carcinogenesis.
Chemical name: Protein-tyrosine-phosphate phosphohydrolase
Registry number: EC 3.1.3.48
(12 Dec 1998)
protein Zero <protein> The major glycoprotein of peripheral nerve myelin, an integral transmembrane protein, synthesised by Schwann cells (Mw = 28, 500).
(18 Nov 1997)
proteolipid protein <protein> Highly conserved membrane protein (30 kD) in myelin. Cellular function obscure but mutations lethal for example jimpy mouse and Pelizaeus Merzbacher disease of man.
(18 Nov 1997)
proto-oncogene protein p21(ras) Cellular protein encoded by the c-ras genes. The protein has GTPase activity and is involved in transmembrane signal transduction as a guanine nucleotide binding protein. Elevated levels of p21 c-ras have been associated with neoplasia.
(12 Dec 1998)
proto-oncogene protein pp60(c-src) <enzyme> Membrane-associated tyrosine-specific kinase encoded by the c-src genes. It has an important role in cellular growth control. Truncation of carboxy-terminal residues in pp60(c-src) leads to pp60(v-src) which has the ability to transform cells. This kinase pp60 c-src should not be confused with csk, also known as c-src kinase.
Registry number: EC 2.7.1.-
(12 Dec 1998)
heterologous protein A protein that differs from any protein normally found in the organism in question.
Synonym: heterologous protein.
(05 Mar 2000)
prp 27-30 protein Protease-resistant core of prpsc, the abnormal isoform of prion proteins (prions). Prp 27-30 is produced by limited proteolysis of the n-terminus of prpsc.
(12 Dec 1998)
high-mobility group protein <protein> An HMG protein is one of a group of various different proteins which are somehow involved with chromatin, but which are not histones and whose exact function is not known.
(09 Oct 1997)
HIV core protein p24 A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by elisa and western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines.
(12 Dec 1998)
HIV envelope protein gp120 External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120,000 kD and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably t4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV.
(12 Dec 1998)
HIV envelope protein gp160 An envelope protein of the human immunodeficiency virus that is encoded by the HIV env gene. It has a molecular weight of 160,000 kD and contains numerous glycosylation sites. It serves as a precursor for both the HIV envelope protein gp120 and the HIV envelope protein gp41.
(12 Dec 1998)
HIV envelope protein gp41 Transmembrane envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The n-terminal part of gp41 is thought to be involved in cell fusion with the CD4 antigens of t4 lymphocytes, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by immunoblotting.
(12 Dec 1998)
PTC protein Formed by the reaction of phenylisothiocyanate with a terminal alpha-amino group of a peptide or protein
See: phenylisothiocyanate, phenylthiohydantoin.
Synonym: PhNCS protein, PTC protein.
(05 Mar 2000)
hn protein Glycoprotein from sendai, para-influenza, newcastle disease, and other viruses that participates in binding the virus to cell-surface receptors. The hn protein possesses both haemagglutinin and neuraminidase activity.
(12 Dec 1998)
secretory protein <protein> In eukaryotes, proteins synthesised on rough endoplasmic reticulum and destined for export. Nearly all proteins secreted from cells are glycosylated (in the Golgi apparatus, although there are exceptions (albumin). In prokaryotes, secreted proteins may be synthesised on ribosomes associated with the plasma membrane or exported post translation.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á